In response: Drug-resistant epilepsy in adults: outcome trajectories after failure of two medications

Authors:

Abstract
No abstract available
Funding Information
  • UCB Pharma
  • H. Lundbeck A/S
  • Eisai
  • Sunovion
  • Allergan
  • National Institute of Mental Health
  • Upsher-Smith
  • Natus